ReviewNature reviews. Gastroenterology & hepatology2013
New treatments for IBS.
Review in Nature reviews. Gastroenterology & hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 31 citations in OpenAlex.
- Ehealth: low FODMAP diet vs Lactobacillus rhamnosus GG in irritable bowel syndrome.World journal of gastroenterology · 2014Trial
- A randomized, double-blind, placebo-controlled study to assess efficacy of mirtazapine for the treatment of diarrhea predominant irritable bowel syndrome.BioPsychoSocial medicine · 2021Article
- Exploring the Potential of RET Kinase Inhibition for Irritable Bowel Syndrome: A Preclinical Investigation in Rodent Models of Colonic Hypersensitivity.The Journal of pharmacology and experimental therapeutics · 2019Article
- Early experience with a low FODMAP diet in Asian patients with irritable bowel syndrome.JGH open : an open access journal of gastroenterology and hepatology · 2018Article
- Discovery of a First-in-Class Gut-Restricted RET Kinase Inhibitor as a Clinical Candidate for the Treatment of IBS.ACS medicinal chemistry letters · 2018Article
- miR-16 and miR-103 impact 5-HTScientific reports · 2017Article
- Board Review Vignette: Irritable Bowel Syndrome.The American journal of gastroenterology · 2016Article
- Efficacy of the low FODMAP diet for treating irritable bowel syndrome: the evidence to date.Clinical and experimental gastroenterology · 2016Review
- Impact of psychological stress on irritable bowel syndrome.World journal of gastroenterology · 2014Review
- Treatment of abdominal pain in irritable bowel syndrome.Journal of gastroenterology · 2014Review
- Complementary and alternative medicines in irritable bowel syndrome: an integrative view.World journal of gastroenterology · 2014Review
- Cognitive-behavioral therapy for the management of irritable bowel syndrome.World journal of gastroenterology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IBS is a common disorder that affects approximately 5-20% of the populations of Western countries; the main symptoms are abdominal pain and erratic, altered bowel habits, often accompanied by bloating. Despite an array of available pharmacological and nonpharmacological treatments aimed at a wide variety of gastrointestinal and brain targets, many patients do not report adequate symptom relief. The effect of IBS on an individual can be enormous, and the societal and financial costs overall are high, which is indicative of an unmet need for effective IBS treatments. Intense research efforts are ongoing that range from the development of new molecules for pharmacological therapies to testing the utility of internet technology to facilitate widespread delivery of efficacious behavioural therapy. This Review discusses the latest treatments for IBS, including novel nonpharmacological and pharmacological approaches. We have included estimates of the number needed to treat and the number needed to harm for selected treatments. Emerging and potential future treatments are included, with the data supporting an optimistic view about the future of IBS therapeutics. The ability to optimize therapy by individualizing management whilst also avoiding harm remains the key to achieving the best possible outcomes with currently available therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.